All In MedTech

Device Trial Radar · NCT04065490

Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III)

A Double-Masked, Randomized, Sham-Controlled, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Photobiomodulation (PBM) in Subjects With Dry Age-Related Macular Degeneration (AMD) (LIGHTSITE III)

Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

100

Actual

Start

Sep 23, 2019

Primary completion

Jan 24, 2023

Study completion Nov 1, 2024

Sponsor

Lead sponsor
LumiThera, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Aug 22, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This LIGHTSITE III study is a double-masked, sham-controlled, parallel design, prospective multi-site study for the use of PBM as a treatment for visual impairment in subjects with dry AMD. Alcon Research, LLC, acquired LumiThera in September 2025.

Conditions

  • Dry Age-related Macular Degeneration

Interventions

  • Valeda Light Delivery SystemDevice

    Light delivery system that produces multi-wavelength LED treatment at 590, 660 and 850 nanometers.

  • Valeda Light Delivery System Sham ModeDevice

    Sham light delivery system that emits an approximate 50 times and 100 times reduction in treatment dose for the 590 and 660 nm wavelengths respectively and no emission of the 850 nm wavelength.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline in Best Corrected Visual Acuity (Letters Read) at Month 21Time frame: Baseline (Day 0, pretreatment), Month 21

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Retina Vitreous Associates Medical Group

    Beverly Hills, California

9 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.